Axillary RT and lymph node surgery yielded comparable outcomes for patients with breast cancer

December 6, 2018, American Association for Cancer Research

Patients with early-stage breast cancer who had cancer detected in a sentinel lymph node biopsy had comparable 10-year recurrence and survival rates following either axillary radiotherapy or axillary lymph node dissection, according to data from the randomized, phase III AMAROS clinical trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.

"Patients with early-stage invasive breast cancer who have no clinical evidence of local spread of disease to axillary (armpit) lymph nodes, meaning that palpation or ultrasound shows no sign of disease spread, undergo a ," said Emiel J. T. Rutgers, MD, Ph.D., the principal investigator of the AMAROS clinical trial and a surgical oncologist at the Netherlands Cancer Institute in Amsterdam. "Traditionally, those patients who had cancer detected in a sentinel lymph node biopsy underwent axillary lymph node dissection, which is an effective but invasive surgical procedure that is associated with adverse side effects such as lymphedema and difficulties moving the arm."

Rutgers; Mila Donker, MD, Ph.D., a at the Netherlands Cancer Institute; and colleagues from the EORTC and ALMANAC breast cancer research organizations, conducted the AMAROS clinical trial to test whether axillary radiotherapy could yield comparable outcomes to axillary lymph node dissection with fewer .

"Our new 10-year data show that axillary radiotherapy and axillary lymph node dissection provide excellent and comparable overall survival, distant-metastasis-free survival, and locoregional control," said Donker. "Given that we previously published five-year follow-up data from the trial showing that lymphedema occurred significantly more often after axillary lymph node dissection than after axillary radiotherapy, we believe that axillary radiotherapy should be considered a good option for patients who have a positive sentinel lymph node biopsy instead of complete surgical clearance of the axillary ."

Updated five-year follow-up information on quality of life and morbidity show again that radiotherapy is associated with significantly less lymphedema as compared to surgery.

Of the 4,806 patients with early-stage, clinically node-negative breast cancer who the researchers enrolled in the trial, 1,425 went on to have a positive sentinel ymph node biopsy; 744 of these patients had been randomly assigned to the axillary lymph node dissection group and 681 to the axillary radiotherapy group.

After 10 years, 1.82 percent (11 out 681 patients) of those assigned to axillary radiotherapy had axillary recurrence, compared with 0.93 percent (7 out of 744 patients) of those assigned to axillary lymph node dissection. In addition, neither distant metastasis-free survival nor overall survival were significantly different between the two treatment arms. Distant metastasis-free survival was 78.2 percent among those assigned to axillary radiotherapy and 81.7 percent among those assigned to axillary lymph node dissection; overall survival in the two arms was 81.4 percent and 84.6 percent, respectively.

A significantly greater proportion of patients assigned to axillary radiotherapy went on to develop a second primary cancer than did patients assigned to axillary lymph node dissection, 11.0 percent versus 7.7 percent. Donker explained that this difference was mainly due to a higher incidence of contralateral breast in the patients treated with axillary radiotherapy. She also noted that since the radiation technique of that time was performed with the use of two tangential fields, the "extra" radiation to the contralateral breast by including an axillary, or periclavicular field is negligible.

"We have found no indication that the increased incidence of second primary cancers is induced by the radiotherapy," said Donker. "Therefore, we strongly believe that axillary radiotherapy is a good alternative to axillary lymph node dissection in this group of patients."

"Data from another recent clinical trial suggested that there may be some patients who do not need axillary treatment even if they have a positive sentinel lymph node biopsy," added Rutgers. "Moving forward, we need to better tailor treatment for each individual patient. Some will still need axillary treatment, and our data indicate that axillary radiotherapy is a good option here."

According to the researchers, the main limitation of the study is that the size of the radiation field was greater than what is currently deemed necessary, which caused some morbidity that may now be avoided. There was also an imbalance in the number of who had a sentinel lymph node biopsy in the two arms and the number of recurrences was by far lower than expected, reducing the statistical power of the study. However, the researchers noted that these limitations do not adversely affect the conclusion from the trial data that axillary is not inferior to axillary lymph node dissections in terms of locoregional control.

Explore further: Fewer early stage breast cancer patients may need lymph node removal: study

Related Stories

Fewer early stage breast cancer patients may need lymph node removal: study

December 6, 2018
(HealthDay)—For many breast cancer patients, removal of lymph nodes in the armpit area is a common procedure, due to worries that the tumor has spread to these tissues.

Study shows radiotherapy and surgery provide regional control for breast cancer patients

June 3, 2013
Final analysis of the EORTC 10981-22023 AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial has shown that both axillary lymph node dissection and axillary radiotherapy provide excellent regional control ...

Breast cancer patients with positive ultrasound guided axillary node biopsy need dissection

May 3, 2012
Contrary to a trend in treatment, breast cancer patients with suspicious lymph nodes should have an ultrasound-guided axillary node biopsy, and if that biopsy is positive these patients should undergo an axillary dissection, ...

Study examines accuracy of test for lymph node metastases in women with breast cancer

April 16, 2018
For patients diagnosed with breast cancer, determining whether cancer cells have spread to the axillary lymph nodes of the armpit is important for guiding treatment decisions. It has been debated whether axillary ultrasound ...

Sentinel lymph node dissection non-inferior to axillary node

September 13, 2017
(HealthDay)—Ten-year overall survival for primary breast cancer patients treated with sentinel lymph node dissection (SLND) alone is similar to that seen in those treated with axillary lymph node dissection (ALND), according ...

Some breast cancer patients on neoadjuvant chemo may avoid axillary lymph node dissection

December 7, 2016
A sentinel lymph node biopsy (SLNB) during surgery that showed no signs of cancer was associated with a low risk for breast cancer recurrence in the axillary (armpit) lymph nodes for patients with large, operable breast tumors ...

Recommended for you

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.